Drug Metabolism and Pharmacokinetics最新文献_第10页

Clinical studies on pharmacogenomics and DDIS involving drug transporters 涉及药物转运体的药物基因组学和 DDIS 临床研究

IF 2.1 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2024-04-01 DOI: 10.1016/j.dmpk.2023.100558

Bridget Morse

引用次数: 0

Can prostaglandins be used as biomarkers for atypical antipsychotic mediated immune system dyregulation in zebra fish? 前列腺素可用作斑马鱼非典型抗精神病药物介导的免疫系统失调的生物标记物吗？

IF 2.1 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2024-04-01 DOI: 10.1016/j.dmpk.2023.100816

Deborah Barlow , William Sampson , Derek Molliver , James Coffman , Meghan May , Karen Houseknecht

引用次数: 0

The effect of clofazimine in modulating intracellular concentrations of remdesivir and GS-441524: A potential mechanism of enhancing antiviral effects against SARS-COV-2 氯法齐明调节雷米替韦和 GS-441524 细胞内浓度的作用：增强 SARS-COV-2 抗病毒效果的潜在机制

IF 2.1 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2024-04-01 DOI: 10.1016/j.dmpk.2023.100804

Md Rasheduzzaman Jony, Jae Gook Shin, Yong Soon Cho, Saurav Howlader, Dong Hyun Kim

引用次数: 0

High throughput and fully automated sample preparation for quantitative bioanalysis using LC/MS/MS 利用 LC/MS/MS 进行生物定量分析的高通量和全自动样品制备技术

IF 2.1 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2024-04-01 DOI: 10.1016/j.dmpk.2023.100812

Anu Marahatta, Sara Abbondondolo, Christopher Roberts, Christopher Strock

引用次数: 0

Protein-bound uremic toxin clearance as biomarkers of kidney tubular function in diabetic kidney disease 作为糖尿病肾病肾小管功能生物标志物的蛋白结合尿毒症毒素清除率

IF 2.1 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2024-04-01 DOI: 10.1016/j.dmpk.2023.100815

Sabbir Ahmed , Rolf Sparidans , Robin Vernooij , Silvia Mihaila , Roel Broekhuizen , Roel Goldschmeding , Tri Nguyen , Hiddo Heerspink , Rosalinde Masereeuw , Karin Gerritsen

引用次数: 0

One size does not fit all: Preclinical tools to characterize the pharmacokinetics and biodistribution of GaINAc-siRNA 不能一刀切：表征 GaINAc-siRNA 药代动力学和生物分布的临床前工具

IF 2.1 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2024-04-01 DOI: 10.1016/j.dmpk.2023.100567

Julie Lade

引用次数: 0

Construction of a fused grid-based CYP2C8-Template system and the application 构建基于融合网格的 CYP2C8 模板系统及其应用

IF 2.1 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2024-04-01 DOI: 10.1016/j.dmpk.2023.100492

Yasushi Yamazoe , Yoshiya Yamamura , Kouichi Yoshinari

{"title":"Construction of a fused grid-based CYP2C8-Template system and the application","authors":"Yasushi Yamazoe , Yoshiya Yamamura , Kouichi Yoshinari","doi":"10.1016/j.dmpk.2023.100492","DOIUrl":"10.1016/j.dmpk.2023.100492","url":null,"abstract":"<div><p>A ligand-accessible space in the CYP2C8 active site was reconstituted as a fused grid-based Template∗ with the use of structural data of the ligands. An evaluation system of CYP2C8-mediated metabolism has been developed on Template with the introduction of the idea of Trigger-residue initiated ligand-movement and fastening. Reciprocal comparison of the data of simulation on Template with experimental results suggested a unified way of the interaction of CYP2C8 and its ligands through the simultaneous plural-contact with Rear-wall of Template. CYP2C8 was expected to have a room for ligands between vertically standing parallel walls termed Facial-wall and Rear-wall. Both the walls were separated by a distance corresponding to 1.5-Ring (grid) diameter size, which was termed Width-gauge. The ligand sittings were stabilized through contacts with Facial-wall and the left-side borders of Template including specific Position 29, left-side border of Rings I/J, or Left-end, after Trigger-residue initiated ligand-movement. Trigger-residue movement is suggested to force ligands to stay firmly in the active site and then to initiate CYP2C8 reactions. Simulation experiments for over 350 reactions of CYP2C8 ligands supported the system established.</p></div>","PeriodicalId":11298,"journal":{"name":"Drug Metabolism and Pharmacokinetics","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135534547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Endosomal escape for intracellular delivery of RNA therapeutics: current and future strategies 用于细胞内输送 RNA 治疗药物的内膜逸出：当前和未来的战略

IF 2.1 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2024-04-01 DOI: 10.1016/j.dmpk.2023.100570

Chris MacLauchlin

引用次数: 0

CYP46A1 inhibition and activation: an in vitro high throughput screening assay to assess possible drug interactions using FDA approved chemical library CYP46A1 的抑制和激活：一种体外高通量筛选试验，利用 FDA 批准的化学库评估可能的药物相互作用

IF 2.1 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2024-04-01 DOI: 10.1016/j.dmpk.2023.100826

Sravani Adusumalli, Megan Metallides, Jennifer Pham, Sarah Strock, Christopher Strock

引用次数: 0

Evaluation of a cost-effective in vitro human model for predicting intrinsic hepatocyte clearance of slowly metabolized compounds 评估经济有效的体外人体模型，以预测缓慢代谢化合物的肝细胞内在清除率

IF 2.1 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2024-04-01 DOI: 10.1016/j.dmpk.2023.100817

Nathan Delvaux, Mitchell Lavarias, Kathleen Sampson, Daniel Albaugh

引用次数: 0